The goal of this Clinical Study is to understand the outcomes by informing therapy choice for
adjuvant treatment in clear cell renal cell carcinoma by using molecular residual disease.
The main question[s] it aims to answer are:
- what is the progression free survival of a cohort of high risk resected RCC patients
when treated based on MRD
- what is the overall survival of high risk resected RCC patients when treated based on
MRD
Participants will forgo adjuvant therapy with pembrolizumab if they have no detectable
molecular residual disease. Participants will continue on with standard of care pembrolizumab
if they do appear to have molecular residual disease.